Canadian Cancer Trials Group Bulletins


Recent Publications

Please remember that you can view final results of completed Canadian Cancer Trials Group trials using the "Primary Publication Dissemination" searchable utility which you can access using this link ...

Canadian Cancer Trials Group IND.181 -- Canadian Cancer Trials Group Phase I Study of AT9283 Given as a 24 Hour Infusion on Days 1 and 8 Every Three Weeks in Patients with Advanced Incurable Malignancy

Dent SF, Gelmon KA, Chi KN, Jonker DJ, Wainman N, Capier CA, Chen EX, Lyons JF, Seymour L Canadian Cancer Trials Group IND.181: Phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies :31(6):1522 -1539,2013.

The authors reported that AT9283 was well tolerated in this study. The RP2D is 40 mg/m2/day on days 1, 8 of a 21-day cycle. Ongoing AT9283 trials will assess efficacy and safety in solid and haematological cancers.

Canadian Cancer Trials Group LY.11 (SWOG S9704) -- A Randomized Phase III Trial Comparing Early High Dose Chemoradiotherapy and an Autologous Stem Cell Transplant to Conventional Dose CHOP Chemotherapy plus Rituximab for CD20+B-Cell Lymphomas (with Possible Late Autologous Stem Cell Transplant)for Patients with Diffuse Aggressive Non-Hodgkin's Lymphoma in the High-Intermediate/High Risk International Classification Prognostic Groups

Investigators found that "early autologous stem-cell transplantation improved progression-free survival among patients with high-intermediate-risk or high-risk disease who had a response to induction therapy. Overall survival after transplantation was not improved, probably because of the effectiveness of salvage transplantation."

Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Stewart DA, Shea TC, Porcu P, Winter JN, Kahl BS, Miller TP, Tubbs RR, Marcellus D, Friedberg JW, Barton KP, Mills GM, LeBlanc M, Rimsza LM, Forman SJ, Fisher RI. Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin's Lymphoma. N Engl J Med 369: 1681-90, 2013.

Liu Y, Litière S, de Vries EG, Sargent D, Shankar L, Bogaerts J, Seymour L. The role of response evaluation criteria in solid tumour in anticancer treatment evaluation: Results of a survey in the oncology community (ONLINE). Eur J Can 2013.

Dancey J. Targeted therapies and clinical trials in ovarian cancer. Ann Oncol 24: 59-63, 2013.